NCT07379658

Long-Acting Injectable HIV PrEP PROs

Improving HIV Prevention Outcomes: Insights on Long-Acting Injectable (LAI) HIV Pre-Exposure Prophylaxis (PrEP) Patient-Reported Medication Preferences, Adherence, and Clinical Outcomes (IMPACT) in a Southern US State

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 128 (estimated)
• Sponsor: Anupama Raghuram MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews. Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.

Conditions

• HIV Pre-exposure Prophylaxis

Interventions

Type	Name	Description
OTHER	Interview and survey to evaluate patient reported outcomes between the two medications.	No intervention, the two cohorts will receive the same surveys and interviews.

Timeline

• Start date: 2026-01-15
• Primary completion: 2028-01-01
• Completion: 2028-01-01
• First posted: 2026-01-30
• Last updated: 2026-01-30

Locations

3 sites across 1 country: United States